
    
      The trial will consist of three stages: 1) a 30 day Phase 2 PK and PD evaluation of
      somavaratan, 2) an optional Phase 2 Extension and 3) a 12 month Phase 3 safety and efficacy
      stage. The study is a randomized, multi-center, open label study. The primary endpoint is
      height velocity at 12 months.
    
  